Research Progress of Artificial Liver in the Treatment of Severe Liver Disease
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v6i2.4060
Abstract
Acute-on-chronic liver failure (ACLF) presents high mortality with limited treatments. Artificial liver support systems (ALSS), including non-biological (NBAL) and bioartificial (BAL) types, offer key supportive strategies. NBAL removes toxins and cytokines, while BAL provides metabolic and regenerative functions. Recent developments in BAL — such as stem cell sourcing, 3D scaffolds, and clinical trials — show promise in improving outcomes. This review outlines the advances, clinical applications, and future prospects of ALSS in achieving individualized, efficient liver failure management.
Keywords
ACLF; artificial liver; NBAL; BAL
Full Text
PDF - Viewed/Downloaded: 2 TimesReferences
[1]Mezzano G, Juanola A, Cardenas A, et al. Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis[J]. Gut, 2022, 71(1): 148-155.
[2]Jindal A, Sarin S K. Epidemiology of liver failure in Asia-Pacific region[J]. Liver International, 2022, 42(9): 2093-2109.
[3]Ling S, Jiang G, Que Q, et al. Liver transplantation in patients with liver failure: Twenty years of experience from China[J]. Liver International, 2022, 42(9): 2110-2116.
[4]Yang Z, Zhang Z, Cheng Q, et al. Plasma perfusion combined with plasma exchange in chronic hepatitis B-related acute-on-chronic liver failure patients[J]. Hepatology International, 2020, 14(4): 491-502.
[5]Chen Y yuan, Li H, Xu B yan, et al. Plasma Exchange-Based Non-bioartificial Liver Support System Improves the Short-Term Outcomes of Patients With Hepatitis B Virus-Associated Acute-on-Chronic Liver Failure: A Multicenter Prospective Cohort Study[J]. Frontiers in Medicine, 2021, 8: 779744.
[6]Xu W, Li Y, Wang L, et al. Efficacy and safety of combination treatment of double plasma molecular adsorption system and low volume plasma exchange for patients with hepatitis B virus related acute-on-chronic liver failure: a multicentre randomised controlled clinical trial[J]. BMJ Open, 2021, 11(12): e047690.
[7]Standard-Volume Plasma Exchange Improves Outcomes in Patients With Acute Liver Failure: A Randomized Controlled Trial - PubMed[EB/OL]. [2025-05-13]. https://pubmed.ncbi.nlm.nih.gov/33524593/.
[8]Burke L, Bernal W, Pirani T, et al. Plasma exchange does not improve overall survival in patients with acute liver failure in a real-world cohort[J]. Journal of Hepatology, 2025, 82(4): 615-621.
[9]Tan H K. Molecular adsorbent recirculating system (MARS)[J]. Annals of the Academy of Medicine, Singapore, 2004, 33(3): 329-335.
[10]Bañares R, Nevens F, Larsen F S, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial[J]. Hepatology, 2013, 57(3): 1153-1162.
[11]Gerth H U, Pohlen M, Thölking G, et al. Molecular Adsorbent Recirculating System Can Reduce Short-Term Mortality Among Patients With Acute-on-Chronic Liver Failure-A Retrospective Analysis[J]. Critical Care Medicine, 2017, 45(10): 1616-1624.
[12]Agarwal B, Cañizares R B, Saliba F, et al. Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on- chronic liver failure[J]. Journal of Hepatology, 2023, 79(1): 79-92.
[13]Weng J, Han X, Zeng F, et al. Fiber scaffold bioartificial liver therapy relieves acute liver failure and extrahepatic organ injury in pigs[J]. Theranostics, 2021, 11(16): 7620-7639.
[14]Feng L, Wang Y, Liu S, et al. In vitro safety and efficacy evaluation of a novel hybrid bioartificial liver system with simulated liver failure serum[J]. The International Journal of Artificial Organs, 2022, 45(5): 523-532.
[15]Feng L, Wang Y, Fu Y, et al. A simple and efficient strategy for cell-based and cell-free-based therapies in acute liver failure: hUCMSCs bioartificial liver[J]. Bioengineering & Translational Medicine, 2023, 8(5): e10552.
[16]Wang Y, Zheng Q, Sun Z, et al. Reversal of liver failure using a bioartificial liver device implanted with clinical-grade human-induced hepatocytes[J]. Cell Stem Cell, 2023, 30(5): 617-631.e8.
[17]Xue W S, Zhang H J, Ke J J, et al. A bioartificial transgenic porcine whole liver expressing human proteins alleviates acute liver failure in pigs[J]. Hepatobiliary & Pancreatic Diseases International, 2023, 22(3): 270-281.
[18]Wu G, Wu D, Lo J, et al. A bioartificial liver support system integrated with a DLM/GelMA-based bioengineered whole liver for prevention of hepatic encephalopathy via enhanced ammonia reduction[J]. Biomaterials Science, 2020, 8(10): 2814-2824.
[19]Tuerxun K, He J, Ibrahim I, et al. Bioartificial livers: a review of their design and manufacture[J]. Biofabrication, 2022, 14(3): 032003.
[20]Lee J H, Lee D H, Lee S, et al. Functional Evaluation of a Bioartificial Liver Support System Using Immobilized Hepatocyte Spheroids in a Porcine Model of Acute Liver Failure[J]. Scientific Reports, 2017, 7(1): 3804.
[21]Zheng Z, Li X, Li Z, et al. Artificial and bioartificial liver support systems for acute and acute-on-chronic hepatic failure: A meta-analysis and meta-regression[J]. Experimental and Therapeutic Medicine, 2013, 6(4): 929-936.
[22]Cui K, Liu C H, Teng X, et al. Association Between Artificial Liver Support System and Prognosis in Hepatitis B Virus-Related Acute-on-Chronic Liver Failure[J]. Infection and Drug Resistance, 2025, Volume 18: 113-126.
[23]Shi R, Hui X, Tong T, et al. Non-bioartificial artificial liver support system in acute liver failure: A comprehensive systematic review and meta-analysis of randomized controlled trials[J]. Clinics and Research in Hepatology and Gastroenterology, 2025, 49(2): 102527.
[2]Jindal A, Sarin S K. Epidemiology of liver failure in Asia-Pacific region[J]. Liver International, 2022, 42(9): 2093-2109.
[3]Ling S, Jiang G, Que Q, et al. Liver transplantation in patients with liver failure: Twenty years of experience from China[J]. Liver International, 2022, 42(9): 2110-2116.
[4]Yang Z, Zhang Z, Cheng Q, et al. Plasma perfusion combined with plasma exchange in chronic hepatitis B-related acute-on-chronic liver failure patients[J]. Hepatology International, 2020, 14(4): 491-502.
[5]Chen Y yuan, Li H, Xu B yan, et al. Plasma Exchange-Based Non-bioartificial Liver Support System Improves the Short-Term Outcomes of Patients With Hepatitis B Virus-Associated Acute-on-Chronic Liver Failure: A Multicenter Prospective Cohort Study[J]. Frontiers in Medicine, 2021, 8: 779744.
[6]Xu W, Li Y, Wang L, et al. Efficacy and safety of combination treatment of double plasma molecular adsorption system and low volume plasma exchange for patients with hepatitis B virus related acute-on-chronic liver failure: a multicentre randomised controlled clinical trial[J]. BMJ Open, 2021, 11(12): e047690.
[7]Standard-Volume Plasma Exchange Improves Outcomes in Patients With Acute Liver Failure: A Randomized Controlled Trial - PubMed[EB/OL]. [2025-05-13]. https://pubmed.ncbi.nlm.nih.gov/33524593/.
[8]Burke L, Bernal W, Pirani T, et al. Plasma exchange does not improve overall survival in patients with acute liver failure in a real-world cohort[J]. Journal of Hepatology, 2025, 82(4): 615-621.
[9]Tan H K. Molecular adsorbent recirculating system (MARS)[J]. Annals of the Academy of Medicine, Singapore, 2004, 33(3): 329-335.
[10]Bañares R, Nevens F, Larsen F S, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial[J]. Hepatology, 2013, 57(3): 1153-1162.
[11]Gerth H U, Pohlen M, Thölking G, et al. Molecular Adsorbent Recirculating System Can Reduce Short-Term Mortality Among Patients With Acute-on-Chronic Liver Failure-A Retrospective Analysis[J]. Critical Care Medicine, 2017, 45(10): 1616-1624.
[12]Agarwal B, Cañizares R B, Saliba F, et al. Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on- chronic liver failure[J]. Journal of Hepatology, 2023, 79(1): 79-92.
[13]Weng J, Han X, Zeng F, et al. Fiber scaffold bioartificial liver therapy relieves acute liver failure and extrahepatic organ injury in pigs[J]. Theranostics, 2021, 11(16): 7620-7639.
[14]Feng L, Wang Y, Liu S, et al. In vitro safety and efficacy evaluation of a novel hybrid bioartificial liver system with simulated liver failure serum[J]. The International Journal of Artificial Organs, 2022, 45(5): 523-532.
[15]Feng L, Wang Y, Fu Y, et al. A simple and efficient strategy for cell-based and cell-free-based therapies in acute liver failure: hUCMSCs bioartificial liver[J]. Bioengineering & Translational Medicine, 2023, 8(5): e10552.
[16]Wang Y, Zheng Q, Sun Z, et al. Reversal of liver failure using a bioartificial liver device implanted with clinical-grade human-induced hepatocytes[J]. Cell Stem Cell, 2023, 30(5): 617-631.e8.
[17]Xue W S, Zhang H J, Ke J J, et al. A bioartificial transgenic porcine whole liver expressing human proteins alleviates acute liver failure in pigs[J]. Hepatobiliary & Pancreatic Diseases International, 2023, 22(3): 270-281.
[18]Wu G, Wu D, Lo J, et al. A bioartificial liver support system integrated with a DLM/GelMA-based bioengineered whole liver for prevention of hepatic encephalopathy via enhanced ammonia reduction[J]. Biomaterials Science, 2020, 8(10): 2814-2824.
[19]Tuerxun K, He J, Ibrahim I, et al. Bioartificial livers: a review of their design and manufacture[J]. Biofabrication, 2022, 14(3): 032003.
[20]Lee J H, Lee D H, Lee S, et al. Functional Evaluation of a Bioartificial Liver Support System Using Immobilized Hepatocyte Spheroids in a Porcine Model of Acute Liver Failure[J]. Scientific Reports, 2017, 7(1): 3804.
[21]Zheng Z, Li X, Li Z, et al. Artificial and bioartificial liver support systems for acute and acute-on-chronic hepatic failure: A meta-analysis and meta-regression[J]. Experimental and Therapeutic Medicine, 2013, 6(4): 929-936.
[22]Cui K, Liu C H, Teng X, et al. Association Between Artificial Liver Support System and Prognosis in Hepatitis B Virus-Related Acute-on-Chronic Liver Failure[J]. Infection and Drug Resistance, 2025, Volume 18: 113-126.
[23]Shi R, Hui X, Tong T, et al. Non-bioartificial artificial liver support system in acute liver failure: A comprehensive systematic review and meta-analysis of randomized controlled trials[J]. Clinics and Research in Hepatology and Gastroenterology, 2025, 49(2): 102527.
Copyright © 2025 Cui Liu, Xiaoping Tan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
